Login
Companies $MNOV
$1.33 -$0.01 (0.6%) After hours
MEDICINOVA INC logo

MEDICINOVA INC

medicinova.com

What Do They Do?

Develops drug candidates for neurological, cancer, respiratory and metabolic diseases, seeking pharmaceutical partners to help complete development and commercialize them.

Who Are Their Customers?

Mayo Foundation for Medical Education and Research contracts for clinical research and pharmacovigilance support; the company expects to rely on strategic partners to commercialize products.

Do Revenues Turn Into Profits?

No. It lost $12M in FY2025.

Operating income, FY2025
−3242% of revenue
▼ −5% (Loss) vs FY2024 (−$12.7M, −759%)
Net income, FY2025
−2929% of revenue
▼ −9% (Loss) vs FY2024 (−$11M, −661%)
Free cash flow, FY2025
−2395% of revenue
▲ +8% (Loss) vs FY2024 (−$10.6M, −637%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +12%
vs $123.3K in Q3 FY2025
Net income
▲ +7% (Loss)
vs −$3.1M in Q3 FY2025

A narrower stated development focus The earlier overview also included addiction, an asthma candidate, a solid-tumor candidate, and idiopathic pulmonary fibrosis; the latest strategy instead centers on ibudilast and tipelukast for neurological, respiratory, cancer, fibrotic and metabolic conditions.

Who Do They Compete With?

Competes with Sanofi, Roche, AB Science, BrainStorm Cell Therapeutics, Ionis Pharmaceuticals, Clene, Kazia Therapeutics, Kintara Therapeutics, Denovo Biopharma, Laminar Pharmaceuticals, TVAX Biomedical, Madrigal Pharmaceuticals, Galectin Therapeutics, Gilead Sciences, Galmed Pharmaceuticals, Pfizer, Novo Nordisk, and Merck

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support